A highly sensitive radioimmunoassay for a-human atrial natriuretic peptide (a-hANP) was established and applied to measure the humanplasma a-hANPlevels. In our assay system, anti-a-hANP antiserum was raised in albino rabbits by intradermally injecting synthetic a-hANPwhich was conjugated with bovine serum albumin. The final antiserum dilution was 1:50,000. Sensitivity was 2 pg/tube and the 50% intercept was at 28 pg/tube. The plasma a-hANP was extracted using a Sep-Pak C-18 cartridge. According to this procedure, the mean recovery was 73.8 ± 3.4% (mean ± SE). The averaged plasma levels of immunoreactive a-hANP (ia-hANP) in normal subjects were 24.8 ± 2.1 pg/tube. In patients with chronic renal failure undergoing hemodialysis, the averaged plasma ia-hANP levels were 56.4 ± 5.0 pg/ml before hemodialysis. Plasma ia-hANP levels were significantly higher in the patients with chronic renal failure than in the normal subjects. After hemodialysis, plasma ia-hANP levels decreased significantly (32.2 ± S.8 pg/ml). These results suggest that the alteration in extracellular fluid volume (EGFV) may affect the plasma levels of ia-hANP in patients with chronic renal failure under hemodialysis; i.e., an increase in ECFVelevates and a decrease in ECFVlowers the circulating levels of a-hANP.
Recently, a-human atrial natriuretic peptide (a-hANP)1^has been thought to be involved in the water and sodium metabolism as well as blood pressure regulation.
Increased plasma (XhANPlevels were reported in a patient with paroxysmal atrial tachycardia. Stretching of the atria by volume overload4^has suggested that blood volume change is one important regulating factor for the a-hANP release from the atria. It is well known that expanded blood volume is frequently observed in renal failure. Thus, to investigate the pathophysiological role of a-hANP, the determination of its level in plasma seems essential.
In the present study, a very sensitive radioimmunoassay system for plasma a-hANP was established, and plasma immunoreactive 0L-hANP(ia-hANP) levels were measured before and after hemodialysis in order to investigate the role of a-hANP in patients undergoing hemodialysis. Then, 100 jUl of antiserum and an equal volume of non-immune rabbit serum (1:100) were added.
MATERIALS AND METHODS

Radioimmunoassay
Tubes were incubated at 4°C for 24 hours. After incubation, the radio-iodinated ce-hANP (4,000-5,000 cpm) in 100 jUl assay buffer was added to the tubes. Forty-eight hours after the addition of the labeled a-hANP, a sufficient amount of anti-rabbit gamma-globulin antiserum was added. After the tubes were centrifuged at 3,000 rpm for 20 min at 4 G, the supernatant was carefully decanted, and the radioactivity in the precipitates was counted by an Aloka autogamma spectrometer. The tubes containing the assay buffer and normal rabbit serum were assigned as the control tube. The counts of the precipitate were expressed as the percent of the control tubes. in Fig. 1 . A good dilution curve was obtained in the range of 1 pg to 125 pg ofa-nANP. Sensitivity was 2 pg/tube with a 95% confidence limit. The 50% intercept was at 28 pg/tube. A 100% crossreactivity was observed in the 1-28 rat ANPand the 5-25 rat ANP, whereas the 7-28 a-hANP showed less cross-reactivity (56%). However, the 18-28 a-hANP showed no cross-reactivity at all. The extracted plasma sample showed a good parallel relationship to the a-hANPstandard curve.
On the other hand, the non-extracted plasma sample showed no parallel dilution curve to the ce-hANP standard curve. When known amounts of a-hANP was added to the plasma, the calculated recovery was 73.8 ± 3.4% (mean ± SE).
Intra-assay and inter-assay coefficients of variation was 4.5% and 5.6%, respectively. Clinical study: Plasma ia-hANP levels in normal subjects were 24.8 ± 2.1 pg/ml. The values for plasma ia-hANP, hematocrit, mean arterial pressure and body weight before and after hemodialysis, in each of the patients are shown in Table   1 . After hemodialysis, the blood pressure and body weight were reduced, while the hematocrit rose significantly.
Plasma ia-hANP levels before hemodialysis were 56.4 ± 5.0 pg/ml, being significantly higher than in normal subjects (Table  1) . After hemodialysis, plasma ia-hANP levels decreased significantly (32.2 ± 2.8 pg/ml) ( Table 1 ).
Significant positive and negative correlations were found between the % change of body weight and that of plasma ia-hANP, and between basal iahANP and the % change of ia-hANP, respectively. Schiffrin et al. These differences appear whether the extraction method was used3' '13^or not. ' In our radioimmunoassaysystem, a non-extracted plasma sample did not show a parallel relationship, and revealed a very high plasma level of ia-hANP. However, using the extraction method by Sep-Pak C-18 cartridge, a good parallel relation has been found between the dilution curve of plasma extract and the standard curve, suggesting that Table 1 . The values of plasma atrial natriuretic peptide (ANP), hematocrit (Ht), mean blood pressure (m-BP) and body weight (BW) before and after hemodialysis in patients undergoing chronic hemodialysis. *Significantly lower or higher than before hemodialysis (P < 0.01).
the extraction procedure is necessary in the measurement of the plasma a-hANP. In our ahANP radioimmunoassay, the sensitivity was 2 pg/tube, and the 50% intercept was at 28 pg/ tube, which is one of the most sensitive methods when compared to the techniques previously reported.3'9~13^Plasma iQ:-hANP levels in normal subjects were 24.8 ± 2.1 pg/ml, in good agreement with the data reported by Schiffrin et al.
and Hartter et al.12Î
n patients with severe right heart failure12' and supraventricular tachycardia,3' 14' elevation of plasma ia-hANP levels were reported in some cases. In patients with heart failure, a-hANP appears to be released as a consequence of increased blood volume. Our results in patients with chronic renal failure indicate that volume expansion elicits the release of a-hANP into the circulation. However, it cannot be excluded that elevation of plasma a-hANPlevels may be due to the blood pressure elevation in some cases or the reduction of metabolism. In our study, high plasma ia-hANP before hemodialysis was then decreased to a remarkable degree after hemodialysis.
It was suggested that the marked decline of increased plasma ia-hANP levels after hemodialysis was caused by the reduciton of plasma volume and a fall in blood pressure. It seems likely that the diminished plasma volume may greatly contribute to this mechanism because of the significant correlation between the % change of body weight and that of plasma ia-hANP. However, the possibility of the dialysis of a-hANP from plasma cannot be excluded. Further studies will be necessary to clarify the mechanism of marked decrease of plasma a-hANP after hemodialysis.
